<DOC>
	<DOCNO>NCT01848769</DOCNO>
	<brief_summary>The rationale investigate systemic availability BDP/B17MP formoterol single oral inhalation CHF 1535 50/6 pMDI v free combination approve BDP Formoterol pMDIs , asthmatic child ( 5 11 year old ) .</brief_summary>
	<brief_title>Clinical Pharmacology Study CHF1535 pMDI 50/6 Âµg Versus The Free Combination In Asthmatic Children 5-11 Years Old</brief_title>
	<detailed_description />
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Male/Female child age 511 year Written inform consent obtain parents/legal representative ( accord local regulation ) minor ( age local regulation permit ) . child stable asthma regular treatment ICS use shortacting inhaled beta2agonists reliever control asthma symptom Forced expiratory volume one second ( FEV1 ) &gt; 70 % predict value ( % pred ) withhold beta2agonist treatment minimum 4 h prior dose period . 6 . A cooperative attitude ability train proper use pMDI spacer device compliant study procedure . Past present diagnosis cardiovascular , renal liver disease Known hypersensitivity active treatment Exacerbation asthma symptom within previous 4 week Inability perform require breathing technique blood sample Hospitalization due exacerbation asthma within 1 month prior inclusion Lower respiratory tract infection within 1 month prior inclusion Disease ( asthma ) might influence outcome study Obesity , i.e . &gt; 97 % weight percentile local standard</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Asthma</keyword>
	<keyword>ICS+LABA</keyword>
	<keyword>Children</keyword>
	<keyword>Inhalation</keyword>
	<keyword>pMDI</keyword>
</DOC>